This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Solazyme IPO: 5 Burning Questions

NEW YORK ( TheStreet) -- This Friday's planned IPO of biofuels company Solazyme (SZYM - Get Report) is getting a lot of attention. Is it just a good short-term green energy-IPO euphoria trade, or a good long-term investment opportunity?

There's evidence from recent IPOs in the green energy space that, in the least, the Solazyme deal could be a good short-term investment. Two companies in the biofuels market went public in the past year that argue in favor of a post-IPO boom for Solazyme, Gevo (GEVO - Get Report) and Amyris (AMRS - Get Report). Gevo, which went public in February, is up 20% since its IPO. Amyris, which went public in September 2010, is up 75% since its IPO.

The performance of these recent biofuel IPOs is reason enough for Solazyme to seize the day. Add the recent rise in the price of oil, which has stabilized around the $100 mark after a pullback, and the company has all the makings of a "buzz" offering. "It's not by accident that Solazyme is looking to do the IPO now," said Lux Research analyst Andrew Soare.

Yet if green energy IPO euphoria has taught investors anything, it's that long-term growth, and sustainable stock market gains, have proven elusive in many cases. In the case of biofuels, the hit or miss nature of a nascent industry remains a key theme. As Lux Research recently noted in a mostly positive view of the biofuel segment growth opportunity, despite years of government incentives, financing, and "a graveyard of failed start-ups, the capacity of bio-based fuels and plastics in the ground today replaces only 3% of fuels and 1% of plastics."

The data on the size of the biofuels market today is the key hurdle: "Even with all the attention from governments, investors and the public, bio-based fuels and materials only occupy a small percentage of total fuel and material consumption," Lux Research stated.

There are some compelling biofuels market growth assumptions, nevertheless. Here are some of the optimistic data points from Lux Research on the biofuels market:
  • The global biofuel capacity will grow 7.8% annually to 53 billion gallons in 2015.
  • Biofuel-based materials will soon grow faster than the opportunity in the fuel market, at 17.7% per year, to reach 8.1 million tons by 2015.
  • The bio-based fuel market is $56 billion, and has grown more than 30% annually since 2005.
  • The materials market currently totals $10.7 billion and has grown 10% a year since 2005.
  • One IPO watcher told TheStreetTV that the Solazyme deal looks like an offering that deserves investor attention.

    "In the short-term, Solazyme and the other stocks in the group should do well, but there are lots of risks as they move closer to commercial scale," said Lux's Soare. "I expect hype will keep their stock prices up for at least the next few quarters," he added.
    1 of 3

    Check Out Our Best Services for Investors

    Action Alerts PLUS

    Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

    Product Features:
    • $2.5+ million portfolio
    • Large-cap and dividend focus
    • Intraday trade alerts from Cramer
    Quant Ratings

    Access the tool that DOMINATES the Russell 2000 and the S&P 500.

    Product Features:
    • Buy, hold, or sell recommendations for over 4,300 stocks
    • Unlimited research reports on your favorite stocks
    • A custom stock screener
    Stocks Under $10

    David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

    Product Features:
    • Model portfolio
    • Stocks trading below $10
    • Intraday trade alerts
    14-Days Free
    Only $9.95
    14-Days Free
    Dividend Stock Advisor

    David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

    Product Features:
    • Diversified model portfolio of dividend stocks
    • Updates with exact steps to take - BUY, HOLD, SELL
    Trifecta Stocks

    Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

    Product Features:
    • Model Portfolio
    • Intra Day Trade alerts
    • Access to Quant Ratings
    Real Money

    More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

    Product Features:
    • Access to Jim Cramer's daily blog
    • Intraday commentary and news
    • Real-time trading forums
    Only $49.95
    14-Days Free
    14-Days Free
    AMRS $1.66 0.00%
    DOW $53.38 0.00%
    CVX $91.35 0.00%
    GEVO $1.43 0.00%
    SZYM $2.99 0.00%


    Chart of I:DJI
    DOW 17,812.19 +19.51 0.11%
    S&P 500 2,089.14 +2.55 0.12%
    NASDAQ 5,102.8080 +0.33 0.01%

    Free Reports

    Top Rated Stocks Top Rated Funds Top Rated ETFs